Reddit Posts
7 Undervalued Penny Stocks With Major Upside
Biotechs With Potential Catalysts This Week: $SPPI $VSTM $APRE $CAPR $CFMS
My Top Biotech Plays to get your Account Positive by the Years End
$CAPR - stock is hovering around $4 bucks. They just signed a worldwide licensing deal with John’s Hopkins University for their exosome technology. They’re leaders in DMD treatment and and future COVID vaccines. This thing should be trading at $12 bucks minimum right now. $100+ in coming years. BULL
Mentions
CAPR, tiny biotech with big short term and long term potential, no waiting, you’ll know by the end of August
Also thinking about taking a long position on CAPR. I have a weight towards CRL over any form of approval, but the implied odds seem worth it. I've been trying to figure out though, what did you make of the cancelling of the ad com and suspension of Verdun. Markets clearly seem to think quite bearish, and the bear hypothesis of Prasad and his new CBER demanding an increased evidentiary standard seems to fit nicely. I don't know if I completely buy it though, for other reasons. Do you have any thoughts?
But right now I’m holding CAPR
PCT, NGENF, and CAPR are my straight gambles rn. However, I make Ralph Wiggum look like Einstein.
Don't know about PCT or NGENF but CAPR was nice today and I sold and last I checked it was up in futures. Also, got in on ASTS late-ish ($50) and feel uneasy because nothing can go vertical this long.
Maybe I shouldn't have sold $30K in ASTS shares to buy $10k each in PCT, NGENF, and CAPR...
i spend $10k each on PCT, CAPR, and NGENF shares today (ralph wiggum voice)
I need confirmation bias for throwing $10k each at shares of PCT, NGENF, and CAPR...sold my ASTS for it...
Just sold about $40k of ASTS in my gambling account and threw it at PCT, NGENF, and CAPR...my only DD is that PCT sounds dope af and my boy is a pharma bro and NGENF and CAPR are his two largest positions by far NFA Ralph Wiggum beats a tambourine inside my skull
just shot my wad on PCT and CAPR
just bought $10k in CAPR and PCT shares...my spirit animal is ralph wiggum
Interesting to see how the FDA is reassessing its approach to gene therapies. Do you think this change will benefit more biotechs besides CAPR?
I've lost $12k between CAPR, RDDT, LUNR, and PCT only one I see possibly coming back in the next 2 years is RDDT. Such is life.
I am new to the stock market, but purchased CAPR about a month or 2 ago. It has been going down. While I don't understand much of your post (I will research some of your terminology and phrases - thanks), it seems your assessment is that CAPR is poised to go up quite a bit, is that right??? And, are you saying that when it does, one should take profits/sell soon thereafter?
good day for the DMD community! Let's go CAPR
Pick up some CAPR before is too late
Tomorrow CAPR will fly like an Italian CAPR-ONI
😃 Now is the time for street guy, $CAPR!😎🤟🇺🇲
I wonder if OP is legit, I was looking into CAPR analysis and I thought he wan onto something until I came across this post on his profile. SPR went down all the way to $24 after this post, and is trading at $33 currently. Makes me question the legitimacy and intent of your posts. @androidmj
So apparently, the shares of many vaccine makers, including Moderna ([MRNA](https://www.tipranks.com/stocks/mrna)), Novavax ([NVAX](https://www.tipranks.com/stocks/nvax)), and BioNTech ([BNTX](https://www.tipranks.com/stocks/bntx)) (BTNX), and gene therapy developers, including Sarepta ([SRPT](https://www.tipranks.com/stocks/srpt)), Solid Biosciences ([SLDB](https://www.tipranks.com/stocks/sldb)), Taysha Gene Therapies ([TSHA](https://www.tipranks.com/stocks/tsha)), Capricor Therapeutics ([CAPR](https://www.tipranks.com/stocks/capr)), and Crispr Therapeutics ([CRSP](https://www.tipranks.com/stocks/crsp)), are moving lower following the resignation of Peter Marks from the Food and Drug Administration. Marks was viewed as one of the biggest FDA advocates of cell and gene therapies. [Vaccine, gene therapy makers fall after Peter Marks resignation - TipRanks.com](https://www.tipranks.com/news/the-fly/vaccine-gene-therapy-makers-fall-after-peter-marks-resignation)
but while they do this, isn't they who got hurt as well by reducing the amount of money they posses with the stakes they already had accumulated towards CAPR?
This is what I was wondering too. Why on earth is the stock dropping so bad given generally positive newsflow coming from CAPR lately?
Depends on your option strategy. My portfolio is currently entirely leaps on KULR, CAPR, RIOT and SOXL as of last Friday. I'll probably average down in April and sit on my hands till Christmas.
**UPDATE:** CAPR has announced an **earnings date (March 19)** and released a new investor deck that includes a **target reimbursement price of $1.2M per year**—slightly higher than my initial expectations. Key takeaways from **Capricor’s March 2025 Investor Deck**: 📌 **15,000–20,000** DMD patients in the U.S. 📌 **200,000** DMD patients worldwide 📌 **$27B+** estimated market size by 2030 📌 **Target reimbursement price** expected to be **similar or higher** than exon-skipping therapies (**$1.2M/year**) (Source: [CAPR Investor Deck – March 2025](https://d1io3yog0oux5.cloudfront.net/_5945d8f28f1592eeef48b5ce9959442b/capricor/db/2227/21450/pdf/CAPR+March+2025.pdf)) I've also added to my position: https://preview.redd.it/9of1karzl4oe1.png?width=1290&format=png&auto=webp&s=b3f7ed73921b5165e965548c027cd2d289764773
Yeah, in a market that’s been tanking, CAPR has been showing relative strength instead of breaking down with everything else. Given the high short interest (\~20%), you’d expect it to bleed more if there wasn’t demand absorbing selling pressure. Could be accumulation, shorts covering on the low, or just strong hands refusing to sell. Either way, it’s not trading like a weak stock—which is worth noting heading into earnings and PDUFA hype.
From Capricor’s March 2025 Investor Deck: • 15,000–20,000 DMD patients in the U.S. • 200,000 DMD patients worldwide • $27B+ market size by 2030 • Target reimbursement price expected to be similar or higher than exon-skipping therapies [investor deck](https://d1io3yog0oux5.cloudfront.net/_5945d8f28f1592eeef48b5ce9959442b/capricor/db/2227/21450/pdf/CAPR+March+2025.pdf)
CAPR has been holding up rather well. So that is what makes you think someone's accumulating?
# **TLDR** --- **Ticker:** CAPR **Direction:** Up **Prognosis:** Buy September $15 Calls **Author's Position:** 910 September $15 Calls, currently showing a $29,506 day gain. **Price Target:** $75-$200+ per share based on potential Deramiocel pricing and revenue. **Catalyst:** March 19th earnings call. Expect updates on cash runway, FDA review, and commercialization details.
The market might be underestimating the FDA's Priority Review significance and the lack of competition. If Deramiocel gets approved, CAPR could see a significant upside. The high short interest could also lead to a squeeze if sentiment shifts.
Appreciate the insight, definitely agree that Sarepta’s gene therapy is seeing strong demand, but it’s targeting skeletal muscle, while CAPR’s Deramiocel is aimed specifically at cardiac muscle, which remains a huge unmet need. Even if Elevidys (Sarepta’s drug) expands to broader age groups, it’s unclear whether it will address the progressive heart failure that kills most DMD patients. Solid Biosciences’ recent data is interesting, but they’re still very early stage compared to CAPR’s BLA submission and priority review. The real near-term competition is limited, and CAPR is already nearing the regulatory finish line. Glad to see a fellow biotech trader here! Agree that lower rates could help the sector rally hard. Good luck on your CRISPR and SLDB plays!
I seen some regards DD on CAPR and full ported today 💀
1. Earnings Reports & Corporate Updates (Q1 & Q2 2025) – These will give insight into Capricor’s financial runway, commercialization readiness, and any FDA interactions. Look for updates on manufacturing scale-up and potential milestone payments. 2. Advisory Committee (AdCom) Meeting Decision – If the FDA doesn’t schedule an AdCom, it’s a bullish sign that they don’t see major issues. If they do, it means more scrutiny and volatility. 3. FDA Communications – If the company drops any PR about FDA interactions (e.g., no major questions, streamlined review), that could boost sentiment. 4. Short Interest & Borrow Rate Trends – If shorts start covering ahead of PDUFA, it could indicate shifting sentiment. 5. Institutional Buying – If funds/hedges start entering, it could signal confidence in approval. 6. Broader Biotech Market – If sentiment in biotech improves (XBI running), CAPR could get tailwinds. If no AdCom is scheduled and earnings show solid execution, adding before run-up season (June-July) might be a strategy. If AdCom happens, expect volatility but also an opportunity if the panel leans positive.
CAPR..Still waiting for the approval..it will be in the next 3 months
Ah, I have read a little about Capricor. Just submitted their drug for muscular dystrophy. When I was looking through the progression of the company I noticed it seems like they have submitted the application prior to running (or completing?) Phase 3 trials. I am not sure if this is normal, but in the other biotechs I've studied, phase 3 ussually is finished prior to the marketing application. I always assumed that data is important to prove the saftey and efficacy of the drug, so either I don't understand this fully (very likley) or they are taking a risk by submitting it this early. What is your case for CAPR? Of you can summarize it. I've seen this stock reccomended by several people.
for that I will give u a bio ticker, (CAPR) - Capricor therapeutics, you can do the dd yourself. i think it could be great. in 2025 or 2026. \#PS; not a financial advice, but i genuinely think this got potential
CAPR and DERM CAPR for the Muscular Dystrophy drug under FDA review currently, expecting an announvemnet of acceptance of data in the next 3 weeks or so then a scheduled PDUFA by end of August. Ground breaking. DERM- conference call at 4:30 est. Have a standard of care drug just recently approved on Nov 4th 2024 and is going to impact SP by 3-4x+ within 2 years and possibly a whole lot sooner
CAPR is submitting BLA this week
Here is what it gave me : Here are some stocks currently experiencing or showing potential for a short squeeze: Arca biopharma Inc. (ABIO): This stock has a short interest of 101.3%1. Torrid Holdings Inc. (CURV): With a short interest of 16.6%1. Pulse Biosciences Inc. (PLSE): This stock has a short interest of 17.3%1. Spirit Airlines Inc. (SAVE): Showing a short interest of 29.3%1. Luminar Technologies Inc. (LAZR): With a short interest of 21.2%1. Capricor Therapeutics Inc. (CAPR): This stock has a short interest of 23.9%1. B. Riley Financial Inc. (RILY): Showing a short interest of 77.9%1. Wrap Technologies Inc. (WRAP): With a short interest of 17.6%1. Beyond Meat Inc. (BYND): This stock has a short interest of 37.9%1. These stocks have high short interest, which indicates a high demand from short sellers and potential for a short squeeze. If you’re considering investing, make sure to do thorough research and consider the risks involved. Are you interested in any specific stock from this list?
Ever hear of CAPR... Buddy of mine was harping on me to get in on it since 2001. Had a bunch of 75%. 80%. 100% moves up & down. I think it was mid-September started rocking from about $3.80 hitting a high of $23... Back down to $14.80 currently. Supposedly it's an exosome therapy not a pharmaceutical based company. Anyone have any thoughts. Like if it hits $7 again is it a $40 play or did my buddy miss the majority of the move from $4 up to $23.
I know for a fact that the CAPR dip yesterday was **literally** a nothing burger. If I played options, I would absolutely buy calls.
CAPR dropped yesterday bc an investigator who's done clinical trial work with them got a warning letter from the FDA that was made public. The company responded saying the warning letter is completely unrelated to their clinical trials.
Upu think CAPR will dump again tomorrow if so 10 or 7.5 puts? Would gave made a killing today if I got on that at open.
What's up with all the rug pulls recently? Today it was CAPR, which recovered nicely AH. It's the only way I've lost money past month but has been happening more recently. LUNR, RKLB a little, ASTS on EC, and today CAPR
Watching $CAPR bounce back to $19 - the warning letter to the doctor isn’t relevant to their BLA (fda application) and the study it is relevant to, she is only the doctor for 1 of the 21 locations.
I'm hella regarded but someone less so should do some DD on CAPR...looks like they might go on a run...my DD is a tingling in my loins
Been doing well this year but got some moonshots with shares on CAPR, URGN, PCT, and RYCEY I would really like to see pay off
did the same. got some moonshots on CAPR, URGN, PCT, and RYCEY
I'm too lazy to do DD but my moonshots are CAPR, URGN, and RYCEY I also ate a lot of paint chips as a kid
CAPR has extreme upside in the comming months years
Keep an eye on CAPR, y'all
VRNA, CAPR, ALT for example
Today would be much worse if it wasn't for CAPR
Stocks I'm still digging and planning on swinging. OKLO, SMR, RDDT, ASTS, CAPR, LUNR Moonshot: NGENF Long: RYCEY
Your PLCE and CAPR predictions didn't age well.
Also, I'm very lazy to write up a DD and will get roasted for using [perplexity.ai](http://perplexity.ai) so I will just say that I like CAPR
Dips bought on: OKLO, CAPR, NVDA, SMR, ASTS, LLY
Hey, CAPR is currently sitting at 1 billion market cap. Days below 500m are over
IHO, if you want to make some money, please do some DD on CAPR
Someone will want to buy me a NA beer when CAPR explodes
NNE: Nano Nuclear Energy Inc. (NNE) is positioned to benefit from the growing demand for small modular nuclear reactors, as highlighted in recent news, which could drive investor interest. The stock has shown strong momentum, with a current price of $23.55, significantly above its 10-day SMA of $19.69 and 20-day EMA of $18.39, indicating bullish sentiment. The RSI levels around 61 suggest moderate overbought conditions, while the MACD histogram at 0.62 supports continued upward momentum. Given the broader market's cautious optimism, NNE's alignment with growth sectors like technology and energy could further bolster its performance. For today's session, consider entering around $23.50, targeting $24.50 as the first price target and $25.50 as the second, with a stop loss at $22. Confidence in reaching the first target is high due to strong sector tailwinds, while the second target holds moderate confidence, contingent on broader market stability. Keep an eye on volume spikes as they may signal increased buying pressure. UG: United-Guardian, Inc. (UG) is currently trading at $12.75, showing a significant downtrend over the past month, with the 10-day SMA at $13.35 and the 30-day SMA at $14.43, indicating bearish momentum. The RSI levels are nearing oversold territory, particularly the 6-day RSI at 31.98, suggesting potential for a short-term bounce but not enough to reverse the trend. The MACD histogram is negative, reinforcing the bearish sentiment. Given the lack of recent news and low trading volume, the stock appears to be under selling pressure, likely exacerbated by broader market uncertainties. For today's session, consider entering a short position around $12.80, with a first price target of $12.50 and a second target of $12.20, setting a stop loss at $13.00 to manage risk. Confidence in reaching the first target is moderate due to technical indicators, while the second target carries lower confidence given potential volatility. Overall, the stock's weak technicals and absence of positive catalysts suggest further downside potential. CAMT: Camtek Ltd (CAMT) is currently trading at $81.06, showing signs of consolidation after a recent decline from highs around $88. The 10-day SMA at $82.35 and the 8-day EMA at $81.95 suggest a bearish short-term trend, with the RSI hovering near 47, indicating neutral momentum but leaning towards oversold conditions. The MACD histogram is positive, hinting at potential bullish divergence, yet the broader market sentiment remains cautious. Given the lack of significant news and current market dynamics, expect CAMT to test support levels around $80. Enter a short position at $81.00, targeting $79.50 as the first price target and $78.00 as the second, with a stop loss at $82.00. Confidence in the first target is moderate due to technical indicators aligning with broader market caution, while the second target carries lower confidence given potential volatility. Stay vigilant for any macroeconomic shifts that could impact tech stocks broadly. CAPR: Capricor Therapeutics Inc (CAPR) is currently trading at $20.12, with recent news of a $75 million public offering indicating a strategic move to bolster its financial position for growth. The stock has shown significant volatility over the past month, with a notable upward trend from a low of $5.42 to its current level, supported by strong volume spikes. Technical indicators suggest a bullish sentiment, with the 10-day SMA at $19.20 and the 8-day EMA at $19.43, both above the current price, indicating potential support. The RSI levels are moderately high, suggesting room for further upside before reaching overbought conditions. Given the broader market's cautious optimism and CAPR's recent momentum, I recommend a long position with an entry around $20.00. Set the first price target at $21.50 with a confidence level of 70%, and a second target at $22.50 with a 60% confidence level, considering potential resistance near these levels. Implement a stop loss at $19.00 to manage downside risk, as the stock could face selling pressure if broader market conditions deteriorate. ACHR: Archer Aviation Inc. (ACHR) is showing strong bullish momentum, with the current price of $3.37 above key moving averages, indicating a potential continuation of the uptrend. The 8-day EMA at $3.15 and the 20-day SMA at $3.07 provide solid support levels, while the RSI values suggest the stock is nearing overbought territory, which could lead to a short-term pullback. The MACD histogram is positive, reinforcing the bullish sentiment. Given the broader market's cautious optimism, ACHR may benefit from the strength in technology sectors. For today's session, consider entering a long position around $3.35, targeting $3.50 as the first price target and $3.60 as the second, with a stop loss at $3.20 to manage downside risk. Confidence in reaching the first target is moderate due to the current technical setup, while the second target carries lower confidence given potential market volatility. Keep an eye on volume spikes for confirmation of buying pressure.
Y'all do some DD on CAPR. My buddy knows the CEO and had him on his biomed podcast. It's his second largest position. I will dick-punch him if he is wrong.
Going to watch CAPR continue to rocket.
CAPR? Already up 300% in 3 months
thoughts on $CAPR? looks insane
CAPR..close to FDA approval…💵💵💵💵
If CAPR goes back down to sub 17 I'm going to sell my left nut on the Chinese black market to load up as much as I can.
I aware, thanks. Talked about it in a follow up post. No position in CAPR at the moment.
If you are still holding CAPR be aware. The are doing a 75mili option tomorrow and the price will drop a lot. Sometimes by 50% if you can, get out. We can grab some more cheap after it falls
You made the right moves: CAPR down and SMMT and WOLF up today
CAPR had a big day didn't it? Very few stocks today it seemed went up all day with no resistance. Did you buy the options before or during the day, and if so what time? I'm just wondering bc that was a good move today. I just had stocks and made some.
Hit 33.40+, 52 week high. Still had 1.50 left in the tank if you got in.at 31.90 or less, where it kept landing. 100 shares, that would be $150, not a bad day. But yeah, you'd have to time it right and have the confidence it would go that high. Nice day though for CAPR.
CAPR, SMMT, and SRRK all rising today
I was invested in CAPR. I sold everything at $20 after a cost average $6.20. I'm not saying it can't go up more I think it's a great company. I have my eyes set elsewhere in terms of risk reward. Good luck to all as always I hope people make money no matter what.
Agree, but it's all about knowing your risk tolerance, too. If you're late, don't go all in, but maybe speculate a few with a low stop limit in mind. CAPR had virtually no resistance through most of the day, and it did indeed go up about another .70+ cents after I posted. If nothing more, maybe some bigger investors on here can see something in it and invest big to increase the squeeze. It looked like it was already squeezing all day with little resistance, and maybe it could break out. It's now at a 52-week high, btw.
Thank you CAPR. Saved my day.
Equity warrants are my new best friend. Prevents me from buying options. I'm up a very very nice amount on the EVGOW you mentioned in one post. Made a very nice chunk of change off CAPR (shittttt, I sold 2 soon + 14% today). I'm 2/2 off your picks in making double digit profit % wise in under a week. I think everyone expects an instant 100%+ profit in like 1-3 days. Im satisfied with a +10% profit in 2 days. The vast majority of the world would blow their load off 10% in 6+ months, let alone 2 days. It could be because I own micro to megas & everything inbetween. I have my own perspective on things. For example: NVDA -5.25% at the time im writing this feels like it hurts more than if a "squeeze" stock was -5.25% (assuming I owned the same amount $ wise). The same can be said about a squeeze stock going up 5% compared to a megacap going up 5%. I didn't get great sleep last night but I assume there is a psychological aspect to this.
I really like RYCEY, ASTS, and CAPR
Obviously, do your own DD. However, I think CAPR could really fly.
I feel like this is a great buying opportunity for CAPR I have to buy my buddy dinner bc of it
Looks like this regard got lucky when he bought CRWD, SMR, RYCEY, and CAPR dips
Buy more CAPR before patient data presentation on Fri
Firmly believe that this is an entry point for CAPR if y'all are looking to make some money.
MM selling CAPR, only to buy when CALR releases long term patient data tomorrow AM - CAPR will 🚀